[A17-54] Nivolumab (squamous cell carcinoma of the head and neck) - Addendum to Commission A17-24
Last updated 17.11.2017
Commission awarded on 09.10.2017 by the Federal Joint Committee (G-BA).
Adult patients with squamous-cell carcinoma of the head and neck with progression during/after platinum-based therapy
Conclusion of dossier assessment A17-24 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-40||Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A17-24||Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V||Commission completed|